NDA 206321 · FDA-approved prescription drug
BLA 022505 · FDA-approved prescription drug
Peptide comparison workspaceCompare status.
Compare status.
Follow the evidence.
Compare any two published peptide or GLP-1 records across evidence status, clinical trials, 42 country verification routes, and qualified US research prices. Each lens stays attached to the source category that can support it.
Search the complete peptide database Download the open evidence index Open the complete 20-board matrix40selectable peptide and medicine records
211linked evidence records
42country verification routes per record
20qualified research price boards
Universal peptide comparison
Compare FDA status, trial coverage, aliases, and evidence.
Choose any two published records. The comparison keeps approved medicines, clinical programs, and research-market listings in their correct categories, including blank-versus-zero rules for the bounded clinical-trial snapshot.
FDA-approved medicine7
Investigational clinical program13
US research price board20
Record count shows published coverage, not evidence quality, safety, or clinical strength.
EuropeBelgië · 18 juli 2026Country selection changes the verification route, not the underlying compound identity.
SAXENDA (Liraglutide) vs EGRIFTA WR (Tesamorelin)
Both rows are exact FDA medicine records. Approval and label fields can be compared directly, but this table does not determine which medicine is safer, more effective, or appropriate for an individual. The country lens is set to België.
Blank means outside this 13-program dataset, not zero trials.
Blank means outside this 13-program dataset, not zero trials.
Local status requires the destination records.
Open exact België guide →Local status requires the destination records.
Open exact België guide →Blank preserves the evidence category. It is not a zero price or a missing medicine cost estimate.
Open qualified matrix →Blank preserves the evidence category. It is not a zero price or a missing medicine cost estimate.
Open qualified matrix →FieldSAXENDA (Liraglutide)EGRIFTA WR (Tesamorelin)
Evidence category
FDA-approved medicine
FDA-approved medicine
Question answered
Exact product approval, label, route, and regulatory record
Exact product approval, label, route, and regulatory record
Aliases and codes
liraglutide, Saxenda, NN2211, NDA 206321, GLP-1 receptor agonist
tesamorelin, Egrifta WR, Egrifta SV, TH9507, BLA 022505, GHRF analog
Family
FDA-approved incretin medicine
FDA-approved GHRF-analog medicine
Sponsor, company, or board
Novo Nordisk Inc.
Theratechnologies Inc.
Current record
NDA 206321 · FDA-approved prescription drug
BLA 022505 · FDA-approved prescription drug
Route or listing detail
Injection · Subcutaneous
Lyophilized powder kit · Subcutaneous
Published evidence coverage
2 linked records
2 linked records
Last checked
July 17, 2026
July 17, 2026
ClinicalTrials.gov snapshot
Not indexed by the current 13-program snapshotBlank is a scope boundary, not evidence that no trial history exists.Open the bounded trial finder →
Not indexed by the current 13-program snapshotBlank is a scope boundary, not evidence that no trial history exists.Open the bounded trial finder →
How to read a peptide comparison
Start with status, then compare the fields that actually match.
Which peptides are FDA approved?
An approved medicine record names the exact active ingredient, brand, application, labeled use, route, and company. A similar peptide name on a research seller page does not inherit that approval.
Browse FDA-approved medicine records →What does investigational mean?
An investigational program is being studied but is not an approved retail product. Compare sponsor, phase, registry records, population, duration, and outcome definitions before interpreting a headline result.
Browse the clinical pipeline →How does country status change a comparison?
A sponsor record, FDA approval, or US research listing is only the starting identity. The destination country’s product record and its separate seller or supply register decide what can be supported locally.
Open the 42-country source router →Can research peptide prices be compared?
Yes, when nominal vial size, visible list price, seller market, availability, and checked date match. Those commercial fields still do not establish clinical equivalence or laboratory quality.
Open the complete price matrix →Intent preserved
One evidence comparison. No silent switch to an unrelated price pair.
You arrived with a named comparison or destination. The result above stays focused on identity, approval status, clinical-trial coverage, and official country records. Research-market prices and seller evidence remain available as separate tools.
Keep the selected records and destination attached while you review the decision dashboard and primary evidence.
Return to the current evidence result ↑Compare only qualified exact-size US research boards, with dated prices, availability, and source coverage.
Open the complete price matrix →Filter sourced listings by exact board, public document access, current availability, and vendor evidence.
Open the peptide vendor finder →Interpretation rule
Comparable fields do not create equivalent compounds.
A board can normalize dollars, milligrams, public evidence access, and availability. It cannot normalize molecular identity, potency, research purpose, clinical evidence, safety, or personal suitability.
Open the evidence-status map